Clinical Trials

Phase 2 Active not recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05063565 2026-03-02

ROWAN

100 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT05303532 2026-02-23

ROSY-D

Phase 3 Enrolling by invitation

214 enrolled

Neoplasms

NCT03911557 2025-11-12

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

14 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT06463665 2025-09-26

VIRO-25

Phase 2 Recruiting

142 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT03847649 2025-06-11

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Phase 2 Recruiting

60 enrolled

Neoplasms

NCT06031233 2025-05-21

MINUTE

Phase 4 Recruiting

679 enrolled

Neoplasms

NCT03406650 2025-05-04

SAKK 06/17

61 enrolled

Phase 1/2 Active not recruiting

Neoplasms

NCT03837899 2024-10-29

Durvalumab and Tremelimumab for Pediatric Malignancies

50 enrolled 59 charts

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT03822351 2024-10-08

COAST

189 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03946800 2024-10-02

A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

Phase 1 Completed

61 enrolled

Neoplasms

NCT03094286 2024-06-24

Durvalumab in HIV-1 Patients With Solid Tumors

20 enrolled 36 charts

Phase 2 Active not recruiting

Neoplasms

NCT04392505 2024-02-29

DART

100 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03206073 2023-10-24

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Phase 1/2 Completed

34 enrolled 18 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT02904954 2023-10-11

Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer

60 enrolled 12 charts